SpeeDx is an Australian-based private company with a portfolio of CE-IVD kits for detection of infectious disease pathogens, sexually transmitted infection (STI), and antimicrobial resistance markers. Proprietary PlexZyme^® technology is the driver behind the entire SpeeDx product portfolio. 

ResistancePlus MG assay simultaneously detects Mycoplasma genitalium and genetic markers for azithromycin resistance. The interest for this unique test has increased in response to updates in management guidelines for Mycoplasma genitalium.

The SpeeDx portfolio also includes a multiplex test for herpes simplex virus (1 and 2), varicella zoster and Treponema pallidum (syphilis). Further tests in the PlexPCR portfolio include plans for a comprehensive multiplex panel for respiratory virus testing.

LINK to SpeeDx